Chief Executive Officer Belén Garijo used the company’s presentation at the 44th J.P. Morgan Healthcare Conference to outline ...

The life sciences industry is primed for growth in 2024 as new life, if you will, is breathed into the industry. In New Jersey, one of the top markets nationwide for the sector, that story is playing ...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck invests more than € 300 million into a new Bioprocessing Production Center in Daejeon, South Korea. The new site is the largest investment by Merck's Life ...

Merck provides 2026 and mid-term forecasts, confirms targets for 2025 Company is ready for more M&A with focus on life sciences, CEO says Shares fall after 2026 outlook announcement, after rising ...

Narrow-moat Merck KGaA's fourth-quarter results reflected continued challenges in its life science and semiconductor end markets. The firm generated results within its target ranges for 2023, albeit a ...

Narrow-moat Merck KGaA MRK delivered weak second-quarter results, and with these trends, management reduced its 2023 outlook. Mild tinkering with our near-term expectations does not materially affect ...

Merck and Siemens have signed a memorandum of understanding (MoU) to enhance their strategic partnership, aimed at accelerating digital transformation in the life sciences sector. Under the expanded ...

After posting revenue increases for six straight years, including double-digit growth in 2021 and 2022, Merck KGaA took a hard fall last year, with its global sales declining by 6% to 21 billion euros ...

The low-profile developer behind a major King’s Cross life sciences scheme will push on and complete the project, even after global pharmaceutical giant Merck pulled out of the building. Merck said on ...